Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong
· Delayed Price · Currency is HKD 69.45
+3.50 (5.31%)
Mar 10, 2026, 4:08 PM HKT
Shanghai Henlius Biotech Revenue
Shanghai Henlius Biotech had revenue of 2.82B CNY in the half year ending June 30, 2025, with 12.76% growth. This brings the company's revenue in the last twelve months to 5.80B, up 2.79% year-over-year. In the year 2024, Shanghai Henlius Biotech had annual revenue of 5.72B with 6.11% growth.
Revenue (ttm)
5.80B CNY
Revenue Growth
+2.79%
P/S Ratio
5.64
Revenue / Employee
1.64M CNY
Employees
3,537
Market Cap
35.84B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biocytogen Pharmaceuticals (Beijing) | 1.53B |
| Shanghai Junshi Biosciences | 2.78B |
| Duality Biotherapeutics | 2.38B |
| 3SBio | 9.94B |
| Genscript Biotech | 6.50B |
| InnoCare Pharma | 1.56B |
| PegBio | -4.25M |
| RemeGen | 3.62B |